Neurocrine Biosciences (NBIX) Retained Earnings (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Retained Earnings for 17 consecutive years, with $724.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 756.8% year-over-year to $724.0 million; the trailing twelve-month figure through Jun 2026 stood at $724.0 million (up 756.8% YoY), and the FY2025 full-year result was $447.7 million, up 1433.22% from the prior year.
• Retained Earnings improved to $724.0 million in Q2 2026 per NBIX's latest filing, from $589.6 million in the prior quarter.
• Across five years, Retained Earnings topped out at $724.0 million in Q2 2026 and bottomed at -$564.3 million in Q2 2022.
• Historically, Retained Earnings has averaged -$69.5 million across 5 years, with a median of -$81.2 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Retained Earnings grew 11.69% in 2023, then jumped 6451.11% in 2026.
• Over 5 years, Retained Earnings stood at -$406.8 million in 2022, then soared by 61.38% to -$157.1 million in 2023, then soared by 118.59% to $29.2 million in 2024, then surged by 1433.22% to $447.7 million in 2025, then surged by 61.72% to $724.0 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $724.0 million, $589.6 million, and $447.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.